Literature DB >> 33489133

New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.

Agostino Guida1, Francesco Perri2, Franco Ionna1, Paolo A Ascierto3, Antonio M Grimaldi3.   

Abstract

Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bisphosphonate‐associated osteonecrosis; ipilimumab; medically compromised patients; medication‐related osteonecrosis of the jaw; target therapy

Year:  2020        PMID： 33489133      PMCID： PMC7813008          DOI： 10.1002/ccr3.3418

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN： 2050-0904


  24 in total

1.  Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications.

Authors:  Ourania Nicolatou-Galitis; Magdalini Migkou; Amanda Psyrri; Aristotle Bamias; Dimitrios Pectasides; Theofanis Economopoulos; Judith E Raber-Durlacher; George Dimitriadis; Meletios A Dimopoulos
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-01-20

2.  Osteonecrosis of the jaw related to bevacizumab.

Authors:  Cherry L Estilo; Monica Fornier; Azeez Farooki; Diane Carlson; George Bohle; Joseph M Huryn
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.

Authors:  Adepitan A Owosho; Ariel Blanchard; Lauren Levi; Arvin Kadempour; Haley Rosenberg; SaeHee K Yom; Azeez Farooki; Monica Fornier; Joseph M Huryn; Cherry L Estilo
Journal:  J Craniomaxillofac Surg       Date:  2015-12-20       Impact factor: 2.078

5.  Osteonecrosis of the jaw a new complication related to Ipilimumab.

Authors:  Adepitan A Owosho; Michael Scordo; SaeHee K Yom; Joseph Randazzo; Paul B Chapman; Joseph M Huryn; Cherry L Estilo
Journal:  Oral Oncol       Date:  2015-10-05       Impact factor: 5.337

Review 6.  Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district.

Authors:  Agostino Ponzetti; Francesco Pinta; Rosella Spadi; Caterina Mecca; Laura Fanchini; Marcello Zanini; Libero Ciuffreda; Patrizia Racca
Journal:  Tumori       Date:  2016-11-11       Impact factor: 2.098

7.  Sunitinib related osteonecrosis of jaw: a case report.

Authors:  Yoram Fleissig; Eran Regev; Hadas Lehman
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-01-02

8.  The relationship of denosumab pharmacology and osteonecrosis of the jaws.

Authors:  John Malan; Kyle Ettinger; Erich Naumann; O Ross Beirne
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-12

9.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

10.  BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer.

Authors:  Marco Donia; Paolo Fagone; Ferdinando Nicoletti; Rikke Sick Andersen; Estrid Høgdall; Per Thor Straten; Mads Hald Andersen; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110
View more
  1 in total

Review 1.  Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider.

Authors:  Brittany A Klein; Muhammad Ali Shazib; Alessandro Villa; Fábio de Abreu Alves; Piamkamon Vacharotayangul; Stephen Sonis; Stefano Fedele; Nathaniel S Treister
Journal:  Front Oral Health       Date:  2022-08-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.